Natural products to prevent drug resistance in cancer chemotherapy: a review

Annals of the New York Academy of Sciences

Volumn 1401, Issue 1, 2017, Pages 19-27

  Yuan, Renyikun ^a   Hou, Ying ^a   Sun, Wen ^a   Yu, Jie ^a   Liu, Xin ^a   Niu, Yanan ^a   Lu, Jin Jian ^a   Chen, Xiuping ^a  

^a University of Macau   (Macao)

Author keywords

cancer; drug resistance; natural products; nonapoptotic cell death

Indexed keywords

2 METHOXY 6 ACETYL 7 METHYLJUGLONE; 3 METHYLADENINE; ALLICIN; ARSENIC TRIOXIDE; ARTESUNATE; BAFILOMYCIN A1; BAICALEIN; CHALCONE; CHLOROQUINE; CURCUMIN; DAUNORUBICIN; DOXORUBICIN; GINSENOSIDE; HYDROXYCHLOROQUINE; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NATURAL PRODUCT; ORIDONIN; PACLITAXEL; POLYPHENOL DERIVATIVE; QUERCETIN; RESVERATROL; ROSIN; SANGUINARINE; SHIKONIN; SOLAMARGINE; TENIPOSIDE; TETRANDRINE; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT;

AUTOPHAGOSOME; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; METHUOSIS; MULTIDRUG RESISTANCE; NECROPTOSIS; ONCOSIS; REVIEW; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; NEOPLASMS; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; AUTOPHAGY; BIOLOGICAL PRODUCTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 85030618230     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.13387     Document Type: Review

References (87)

1. McGuire, S. 2016. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv. Nutr. 7: 418–419.
2. Siegel, R.L., K.D. Miller & A. Jemal. 2017. Cancer statistics, 2017. CA Cancer J. Clin. 67: 7–30.
3. MacDonald, V. 2009. Chemotherapy: managing side effects and safe handling. Can. Vet. J. 50: 665–668.
4. Carelle, N., E. Piotto, A. Bellanger, et al. 2002. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95: 155–163.
5. Shaffer, B.C., J.P. Gillet, C. Patel, et al. 2012. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist. Updat. 15: 62–69.
6. Wang, Z., Y. Li, A. Ahmad, et al. 2010. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist. Updat. 13: 109–118.
7. Longley, D.B. & P.G. Johnston. 2005. Molecular mechanisms of drug resistance. J. Pathol. 205: 275–292.
8. Ren, F., J. Shen, H. Shi, et al. 2016. Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer. Biochim. Biophys. Acta 1866: 266–275.
9. Dean, M., Y. Hamon & G. Chimini. 2001. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42: 1007–1017.
10. Choi, C.-H. 2005. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5: 30.
11. Illmer, T., M. Schaich, U. Platzbecker, J. Freiberg-Richter, et al. 2004. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18: 401–408.
12. Li, C., B.Q. Sun & X.D. Gai. 2014. Compounds from Chinese herbal medicines as reversal agents for P-glycoprotein-mediated multidrug resistance in tumours. Clin. Transl. Oncol. 16: 593–598.
13. Borst, P., R. Evers, M. Kool & J. Wijnholds. 2000. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92: 1295–1302.
14. Efferth, T., M. Davey, A. Olbrich, G. Rücker, et al. 2002. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis. 28: 160–168.
15. Austin Doyle, L. & D.D. Ross. 2003. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340–7358.
16. Burger, H., J.A. Foekens, M.P. Look, M.E. Meijer-van Gelder, et al. 2003. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer. Clin. Cancer Res. 9: 827–836.
17. Nabekura, T. 2010. Overcoming multidrug resistance in human cancer cells by natural compounds. Toxins 2: 1207–1224.
18. Dinic, J., A. Podolski-Renic, T. Stankovic, J. Bankovic, et al. 2015. New approaches with natural product drugs for overcoming multidrug resistance in cancer. Curr. Pharm. Des. 21: 5589–5604.
19. Senthilkumar, R., C. Bao-An, C. Xiao-Hui & F. Rong. 2014. Anticancer and multidrug-resistance reversing potential of traditional medicinal plants and their bioactive compounds in leukemia cell lines. Chin. J. Nat. Med. 12: 881–894.
20. Igney, F.H. & P.H. Krammer. 2002. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2: 277–288.
21. Degterev, A., Z. Huang, M. Boyce, Y. Li, et al. 2005. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1: 112–119.
22. Robinson, N., S. McComb, R. Mulligan, R. Dudani, et al. 2012. Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat. Immunol. 13: 954–962.
23. Upton, J.W., W.J. Kaiser & E.S. Mocarski. 2012. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 11: 290–297.
24. Thon, L., S. Mathieu, D. Kabelitz & D. Adam. 2006. The murine TRAIL receptor signals caspase-independent cell death through ceramide. Exp. Cell Res. 312: 3808–3821.
25. Han, W., L. Li, S. Qiu, Q. Lu, et al. 2007. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol. Cancer Ther. 6: 1641–1649.
26. Ermolaeva, M.A., M.-C. Michallet, N. Papadopoulou, et al. 2008. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat. Immunol. 9: 1037–1046.
27. Vanlangenakker, N., M.J. Bertrand, P. Bogaert, P. Vandenabeele, et al. 2011. TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members. Cell Death Dis. 2: e230.
28. Ye, Y.C., H.J. Wang, L. Yu, S. Tashiro, et al. 2012. RIP1-mediated mitochondrial dysfunction and ROS production contributed to tumor necrosis factor alpha-induced L929 cell necroptosis and autophagy. Int. Immunopharmacol. 14: 674–682.
29. Moriwaki, K., J. Bertin, P.J. Gough, G.M. Orlowski, et al. 2015. Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis. 6: e1636.
30. Vanlangenakker, N., T. Vanden Berghe, P. Bogaert, B. Laukens, et al. 2011. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 18: 656–665.
31. Vandenabeele, P., L. Galluzzi, T. Vanden Berghe & G. Kroemer. 2010. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 11: 700–714.
32. Zhang, D.W., J. Shao, J. Lin, et al. 2009. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325: 332–336.
33. Schenk, B. & S. Fulda. 2015. Reactive oxygen species regulate Smac mimetic/TNF alpha-induced necroptotic signaling and cell death. Oncogene 34: 5796–5806.
34. Xuan, Y. & X. Hu. 2009. Naturally-occurring shikonin analogues—a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett. 274: 233–242.
35. 2-dependent JNK activation in cancer cells. Free Radic. Biol. Med. 92: 61–77.
36. Sun, W., X. Wu, H. Gao, et al. 2017. Cytosolic calcium mediates RIP1/RIP3 complex-dependent necroptosis through JNK activation and mitochondrial ROS production in human colon cancer cells. Free Radic. Biol. Med. 108: 433–444.
37. Harris, P.A., S.B. Berger, J.U. Jeong, et al. 2017. Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. J. Med. Chem. 60: 1247–1261.
38. Zhang, X., L.X. Chen, L. Ouyang, et al. 2012. Plant natural compounds: targeting pathways of autophagy as anti-cancer therapeutic agents. Cell Prolif. 45: 466–476.
39. Mizushima, N. 2007. Autophagy: process and function. Genes Dev. 21: 2861–2873.
40. Wang, S.-Y., Q.-J. Yu, R.-D. Zhang & B. Liu. 2011. Core signaling pathways of survival/death in autophagy-related cancer networks. Int. J. Biochem. Cell Biol. 43: 1263–1266.
41. Kanazawa, T., I. Taneike, R. Akaishi, et al. 2004. Amino acids and insulin control autophagic proteolysis through different signaling pathways in relation to mTOR in isolated rat hepatocytes. J. Biol. Chem. 279: 8452–8459.
42. Kondo, Y., T. Kanzawa, R. Sawaya & S. Kondo. 2005. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5: 726–734.
43. Mordier, S., C. Deval, D. Bechet, et al. 2000. Leucine limitation induces autophagy and activation of lysosome-dependent proteolysis in C2C12 myotubes through a mammalian target of rapamycin-independent signaling pathway. J. Biol. Chem. 275: 29900–29906.
44. Kang, R., H.J. Zeh, M.T. Lotze & D. Tang. 2011. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 18: 571–580.
45. Yousefi, S., R. Perozzo, I. Schmid, et al. 2006. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat. Cell Biol. 8: 1124–1132.
46. Mizushima, N., T. Yoshimori & Y. Ohsumi. 2011. The role of Atg proteins in autophagosome formation. Annu. Rev. Cell Dev. Biol. 27: 107–132.
47. Turcotte, S. & A.J. Giaccia. 2010. Targeting cancer cells through autophagy for anticancer therapy. Curr. Opin. Cell Biol. 22: 246–251.
48. Kouroku, Y., E. Fujita, I. Tanida, et al. 2007. ER stress (PERK/eIF2alpha phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. Cell Death Differ. 14: 230–239.
49. Dall'Armi, C., K.A. Devereaux & G. Di Paolo. 2013. The role of lipids in the control of autophagy. Curr. Biol. 23: R33–R45.
50. Levine, B. & G. Kroemer. 2008. SnapShot: macroautophagy. Cell 132: 162.e1–162.e3.
51. Sun, S.Y. 2011. Understanding the role of the death receptor 5/FADD/caspase-8 death signaling in cancer metastasis. Mol. Cell. Pharmacol. 3: 31–34.
52. Qian, W., J. Liu, J. Jin, et al. 2007. Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1. Leuk. Res. 31: 329–339.
53. Goussetis, D.J., J.K. Altman, H. Glaser, et al. 2010. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J. Biol. Chem. 285: 29989–29997.
54. Kanzawa, T., L. Zhang, L. Xiao, et al. 2005. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 24: 980–991.
55. Kanzawa, T., Y. Kondo, H. Ito, et al. 2003. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 63: 2103–2108.
56. Thyagarajan, A., A. Jedinak, H. Nguyen, et al. 2010. Triterpenes from Ganoderma lucidum induce autophagy in colon cancer through the inhibition of p38 mitogen-activated kinase (p38 MAPK). Nutr. Cancer 62: 630–640.
57. Puissant, A., G. Robert, N. Fenouille, et al. 2010. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res. 70: 1042–1052.
58. Cui, Q., S.-I. Tashiro, S. Onodera, et al. 2007. Oridonin induced autophagy in human cervical carcinoma HeLa cells through Ras, JNK, and P38 regulation. J. Pharmacol. Sci. 105: 317–325.
59. Chu, Y.-L., C.-T. Ho, J.-G. Chung, et al. 2012. Allicin induces p53-mediated autophagy in Hep G2 human liver cancer cells. J. Agric. Food Chem. 60: 8363–8371.
60. Chen, S., S.K. Rehman, W. Zhang, et al. 2010. Autophagy is a therapeutic target in anticancer drug resistance. Biochim. Biophys. Acta 1806: 220–229.
61. Qadir, M., B. Kwok, W. Dragowska, et al. 2008. Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res. Treat. 112: 389–403.
62. Boya, P., R.-A. González-Polo, N. Casares, et al. 2005. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 25: 1025–1040.
63. Cook, K.L., A. Warri, D.R. Soto-Pantoja, et al. 2014. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin. Cancer Res. 20: 3222–3232.
64. Clarke, R., A.N. Shajahan, R.B. Riggins, et al. 2009. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J. Steroid Biochem. Mol. Biol. 114: 8–20.
65. Cook, K.L., A.N. Shajahan, A. Wärri, et al. 2012. Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res. 72: 3337–3349.
66. Escobar, M.L., G.H. Vázquez-Nin & O.M. Echeverría. 2011. Oncosis. In Cell Death in Mammalian Ovary. G.H. Vázquez-Nin, M.L. Escobar, M. De Felici, O.M. Echeverría & F.G. Klinger, Eds.: 103–110. Dordrecht: Springer.
67. Weerasinghe, P. & L.M. Buja. 2012. Oncosis: an important non-apoptotic mode of cell death. Exp. Mol. Pathol. 93: 302–308.
68. Mills, E.M., D. Xu, M.M. Fergusson, et al. 2002. Regulation of cellular oncosis by uncoupling protein 2. J. Biol. Chem. 277: 27385–27392.
69. Liu, X., T. Van Vleet & R.G. Schnellmann. 2004. The role of calpain in oncotic cell death. Annu. Rev. Pharmacol. Toxicol. 44: 349–370.
70. Chen, M., H. He, S. Zhan, et al. 2001. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J. Biol. Chem. 276: 30724–30728.
71. Ma, F., C. Zhang, K. Prasad, et al. 2001. Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death. Proc. Natl. Acad. Sci. U.S.A. 98: 9778–9783.
72. Gu, S., X.C. Yang, X.Y. Xiang, et al. 2015. Sanguinarine-induced apoptosis in lung adenocarcinoma cells is dependent on reactive oxygen species production and endoplasmic reticulum stress. Oncol. Rep. 34: 913–919.
73. Pallichankandy, S., A. Rahman, F. Thayyullathil & S. Galadari. 2015. ROS-dependent activation of autophagy is a critical mechanism for the induction of anti-glioma effect of sanguinarine. Free Radic. Biol. Med. 89: 708–720.
74. Weerasinghe, P., S. Hallock, S.C. Tang, et al. 2006. Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells. Exp. Toxicol. Pathol. 58: 21–30.
75. Weerasinghe, P., S. Hallock, S.-C. Tang & A. Liepins. 2001. Sanguinarine induces bimodal cell death in K562 but not in high Bcl-2-expressing JM1 cells. Pathol. Res. Pract. 197: 717–726.
76. Ding, Z., S.C. Tang, P. Weerasinghe, et al. 2002. The alkaloid sanguinarine is effective against multidrug resistance in human cervical cells via bimodal cell death. Biochem. Pharmacol. 63: 1415–1421.
77. Sun, L., Y. Zhao, H. Yuan, et al. 2011. Solamargine, a steroidal alkaloid glycoside, induces oncosis in human K562 leukemia and squamous cell carcinoma KB cells. Cancer Chemother. Pharmacol. 67: 813–821.
78. Du, J.H., H.D. Zhang, Z.J. Ma & K.M. Ji. 2010. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother. Pharmacol. 65: 895–902.
79. Luo, D., Q. Ni, A. Ji, et al. 2016. Dehydroabietic acid derivative QC4 induces gastric cancer cell death via oncosis and apoptosis. Biomed. Res. Int. 2016: 2581061.
80. Zhou, X., W.J. Sun, W.M. Wang, et al. 2013. Artesunate inhibits the growth of gastric cancer cells through the mechanism of promoting oncosis both in vitro and in vivo. Anti-Cancer Drugs 24: 920–927.
81. Maltese, W.A. & J.H. Overmeyer. 2014. Methuosis: nonapoptotic cell death associated with vacuolization of macropinosome and endosome compartments. Am. J. Pathol. 184: 1630–1642.
82. Schnatwinkel, C., S. Christoforidis, M.R. Lindsay, et al. 2004. The Rab5 effector rabankyrin-5 regulates and coordinates different endocytic mechanisms. PLoS Biol. 2: e261.
83. Bhanot, H., A.M. Young, J.H. Overmeyer & W.A. Maltese. 2010. Induction of nonapoptotic cell death by activated Ras requires inverse regulation of Rac1 and Arf6. Mol. Cancer Res. 8: 1358–1374.
84. Manara, M.C., M. Terracciano, C. Mancarella, et al. 2016. CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. Oncotarget 7: 79925–79942.
85. Overmeyer, J.H., A.M. Young, H. Bhanot & W.A. Maltese. 2011. A chalcone-related small molecule that induces methuosis, a novel form of non-apoptotic cell death, in glioblastoma cells. Mol. Cancer 10: 69–86.
86. Shubin, A.V., I.V. Demidyuk, A.A. Komissarov, et al. 2016. Cytoplasmic vacuolization in cell death and survival. Oncotarget 7: 55863–55889.
87. Bishayee, A. & G. Sethi. 2016. Bioactive natural products in cancer prevention and therapy: progress and promise. Semin. Cancer Biol. 40: 1–3.